Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neogenomics Inc
(NQ:
NEO
)
16.39
+1.00 (+6.50%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Neogenomics Inc
< Previous
1
2
3
4
5
6
7
Next >
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
November 19, 2024
From
NeoGenomics, Inc.
Via
Business Wire
Felicia Williams Joins NeoGenomics Board of Directors
November 14, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 08, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports Third Quarter 2024 Results
November 05, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test
October 22, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024
October 15, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia
October 08, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation
September 23, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
September 11, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports Second Quarter 2024 Results
July 29, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024
July 09, 2024
From
NeoGenomics, Inc.
Via
Business Wire
Fort Myers’ Mayor to Proclaim June as NeoGenomics’ Commitment to Cancer Month
June 13, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
May 28, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports First Quarter 2024 Results
April 30, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Announces Senior Leadership Promotions
April 18, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
April 09, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
March 27, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
March 20, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
March 01, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports Fourth Quarter and Full Year 2023 Results
February 20, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
February 01, 2024
From
NeoGenomics, Inc.
Via
Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024
From
FN Media Group LLC
Via
GlobeNewswire
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
January 30, 2024
From
NeoGenomics, Inc.
Via
Business Wire
ROSEN, A LEADING NATIONAL FIRM, Encourages NeoGenomics, Inc. Investors to Inquire About Securities Class Action Investigation – NEO
January 02, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Appeal Ruling
December 28, 2023
Via
ACCESSWIRE
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
December 05, 2023
Via
ACCESSWIRE
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference
November 14, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.